Originally published by our sister publication Pharmacy Practice News
The results of an interim analysis from a second pivotal phase 3 clinical trial investigating the use of Gilead’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, found that it reduced HIV infections by 96% compared with background HIV incidence (bHIV).
The PURPOSE 2 trial (ClinicalTrials.gov Identifier: NCT04925752), a multicenter, randomized double-blind study, is evaluating the safety and